壳聚糖衍生物与头孢他啶的控释及抗菌活性研究

IF 4.3 3区 化学 Q2 CHEMISTRY, MULTIDISCIPLINARY
ACS Omega Pub Date : 2025-09-24 DOI:10.1021/acsomega.5c06901
Luizângela da Silva Reis, , , Roosevelt D. S. Bezerra*, , , Humberto M. Barreto, , , Josy A. Osajima, , and , Edson C. Silva-Filho, 
{"title":"壳聚糖衍生物与头孢他啶的控释及抗菌活性研究","authors":"Luizângela da Silva Reis,&nbsp;, ,&nbsp;Roosevelt D. S. Bezerra*,&nbsp;, ,&nbsp;Humberto M. Barreto,&nbsp;, ,&nbsp;Josy A. Osajima,&nbsp;, and ,&nbsp;Edson C. Silva-Filho,&nbsp;","doi":"10.1021/acsomega.5c06901","DOIUrl":null,"url":null,"abstract":"<p >The search for new low-cost and nontoxic materials with the potential for controlled drug release and antibacterial activity has intensified recently. Due to their unique properties, chitosan derivatives have emerged as promising candidates for these applications. This study evaluated the ability of three chitosan derivatives to incorporate and control the release of the ceftazidime (CFZ) drug, as well as to investigate the antibacterial activity of these derivatives when combined with CFZ against <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>. Initially, the incorporation of the CFZ drug into chitosan derivatives obtained via sequential modification with acetylacetone (CS-AC) and subsequently with ethylenediamine (CS-AC-EN) or diethylenetriamine (CS-AC-DIEN) was evaluated. The adsorption isotherms were best described by the Temkin model. The maximum adsorption capacities were 24.00 ± 0.20 μg mg<sup>–</sup><sup>1</sup> (CS-AC), 20.10 ± 0.70 μg mg<sup>–</sup><sup>1</sup> (CS-AC-EN), and 25.50 ± 0.50 μg mg<sup>–</sup><sup>1</sup> (CS-AC-DIEN). In gastric medium, the chitosan derivatives exhibited rapid CFZ release within the first 30 min: 47.06 ± 0.80% (CS-AC), 53.84 ± 0.30% (CS-AC-EN), and 21.87 ± 0.60% (CS-AC-DIEN). By contrast, at intestinal pH, the release was slower and controlled, reaching 50.38 ± 0.10% for CS-AC at 72 h, 11.88 ± 0.50% for CS-AC-EN at 24 h, and 5.08 ± 0.30% for CS-AC-DIEN at 6 h. The release profiles were best fitted by the Korsmeyer–Peppas kinetic model. Antibacterial assays against <i>S. aureus</i> and <i>E. coli</i> showed that all three chitosan derivatives combined with CFZ outperformed CFZ alone and the mixture of unmodified chitosan with CFZ. The advantage was most pronounced after 72 h: against <i>E. coli</i>, all derivatives achieved &gt;90% inhibition. These findings indicate that the chitosan derivatives are promising materials for controlling CFZ release in gastric and intestinal environments. Furthermore, when combined with CFZ, these derivatives demonstrate significant potential for antibacterial applications against Gram-positive and Gram-negative bacteria.</p>","PeriodicalId":22,"journal":{"name":"ACS Omega","volume":"10 39","pages":"45982–45991"},"PeriodicalIF":4.3000,"publicationDate":"2025-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://pubs.acs.org/doi/pdf/10.1021/acsomega.5c06901","citationCount":"0","resultStr":"{\"title\":\"Chitosan Derivatives Associated with Ceftazidime: Study of Controlled Release and Antibacterial Activity\",\"authors\":\"Luizângela da Silva Reis,&nbsp;, ,&nbsp;Roosevelt D. S. Bezerra*,&nbsp;, ,&nbsp;Humberto M. Barreto,&nbsp;, ,&nbsp;Josy A. Osajima,&nbsp;, and ,&nbsp;Edson C. Silva-Filho,&nbsp;\",\"doi\":\"10.1021/acsomega.5c06901\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p >The search for new low-cost and nontoxic materials with the potential for controlled drug release and antibacterial activity has intensified recently. Due to their unique properties, chitosan derivatives have emerged as promising candidates for these applications. This study evaluated the ability of three chitosan derivatives to incorporate and control the release of the ceftazidime (CFZ) drug, as well as to investigate the antibacterial activity of these derivatives when combined with CFZ against <i>Staphylococcus aureus</i> and <i>Escherichia coli</i>. Initially, the incorporation of the CFZ drug into chitosan derivatives obtained via sequential modification with acetylacetone (CS-AC) and subsequently with ethylenediamine (CS-AC-EN) or diethylenetriamine (CS-AC-DIEN) was evaluated. The adsorption isotherms were best described by the Temkin model. The maximum adsorption capacities were 24.00 ± 0.20 μg mg<sup>–</sup><sup>1</sup> (CS-AC), 20.10 ± 0.70 μg mg<sup>–</sup><sup>1</sup> (CS-AC-EN), and 25.50 ± 0.50 μg mg<sup>–</sup><sup>1</sup> (CS-AC-DIEN). In gastric medium, the chitosan derivatives exhibited rapid CFZ release within the first 30 min: 47.06 ± 0.80% (CS-AC), 53.84 ± 0.30% (CS-AC-EN), and 21.87 ± 0.60% (CS-AC-DIEN). By contrast, at intestinal pH, the release was slower and controlled, reaching 50.38 ± 0.10% for CS-AC at 72 h, 11.88 ± 0.50% for CS-AC-EN at 24 h, and 5.08 ± 0.30% for CS-AC-DIEN at 6 h. The release profiles were best fitted by the Korsmeyer–Peppas kinetic model. Antibacterial assays against <i>S. aureus</i> and <i>E. coli</i> showed that all three chitosan derivatives combined with CFZ outperformed CFZ alone and the mixture of unmodified chitosan with CFZ. The advantage was most pronounced after 72 h: against <i>E. coli</i>, all derivatives achieved &gt;90% inhibition. These findings indicate that the chitosan derivatives are promising materials for controlling CFZ release in gastric and intestinal environments. Furthermore, when combined with CFZ, these derivatives demonstrate significant potential for antibacterial applications against Gram-positive and Gram-negative bacteria.</p>\",\"PeriodicalId\":22,\"journal\":{\"name\":\"ACS Omega\",\"volume\":\"10 39\",\"pages\":\"45982–45991\"},\"PeriodicalIF\":4.3000,\"publicationDate\":\"2025-09-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://pubs.acs.org/doi/pdf/10.1021/acsomega.5c06901\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ACS Omega\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://pubs.acs.org/doi/10.1021/acsomega.5c06901\",\"RegionNum\":3,\"RegionCategory\":\"化学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MULTIDISCIPLINARY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ACS Omega","FirstCategoryId":"92","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acsomega.5c06901","RegionNum":3,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

摘要

寻找新的低成本和无毒的材料,具有控制药物释放和抗菌活性的潜力,最近加强了。由于其独特的性质,壳聚糖衍生物已成为这些应用的有希望的候选者。本研究评估了三种壳聚糖衍生物对头孢他啶(CFZ)药物的结合和控制释放的能力,并研究了这些衍生物与CFZ联合对金黄色葡萄球菌和大肠杆菌的抑菌活性。首先,通过乙酰丙酮(CS-AC)和乙二胺(CS-AC- en)或二乙烯三胺(CS-AC- dien)的顺序修饰得到壳聚糖衍生物,并对CFZ药物的掺入进行了评价。吸附等温线最好用Temkin模型来描述。最大吸附量分别为24.00±0.20 μg mg-1 (CS-AC)、20.10±0.70 μg mg-1 (CS-AC- en)和25.50±0.50 μg mg-1 (CS-AC- dien)。在胃介质中,壳聚糖衍生物的CFZ在前30 min内释放速度较快,分别为47.06±0.80% (CS-AC)、53.84±0.30% (CS-AC- en)和21.87±0.60% (CS-AC- dien)。而在肠道pH下,CS-AC的释放速度较慢且受控制,72 h时为50.38±0.10%,24 h时为11.88±0.50%,6 h时为5.08±0.30%,符合korsmemeyer - peppas动力学模型。对金黄色葡萄球菌和大肠杆菌的抑菌试验表明,三种壳聚糖衍生物与CFZ的联合抑菌效果均优于单独使用CFZ和未改性壳聚糖与CFZ的混合抑菌效果。72h后优势最为明显:对大肠杆菌,所有衍生物均达到90%的抑制作用。这些结果表明壳聚糖衍生物是控制CFZ在胃和肠道环境中释放的有前景的材料。此外,当与CFZ结合时,这些衍生物显示出对革兰氏阳性和革兰氏阴性细菌的抗菌应用的巨大潜力。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Chitosan Derivatives Associated with Ceftazidime: Study of Controlled Release and Antibacterial Activity

The search for new low-cost and nontoxic materials with the potential for controlled drug release and antibacterial activity has intensified recently. Due to their unique properties, chitosan derivatives have emerged as promising candidates for these applications. This study evaluated the ability of three chitosan derivatives to incorporate and control the release of the ceftazidime (CFZ) drug, as well as to investigate the antibacterial activity of these derivatives when combined with CFZ against Staphylococcus aureus and Escherichia coli. Initially, the incorporation of the CFZ drug into chitosan derivatives obtained via sequential modification with acetylacetone (CS-AC) and subsequently with ethylenediamine (CS-AC-EN) or diethylenetriamine (CS-AC-DIEN) was evaluated. The adsorption isotherms were best described by the Temkin model. The maximum adsorption capacities were 24.00 ± 0.20 μg mg1 (CS-AC), 20.10 ± 0.70 μg mg1 (CS-AC-EN), and 25.50 ± 0.50 μg mg1 (CS-AC-DIEN). In gastric medium, the chitosan derivatives exhibited rapid CFZ release within the first 30 min: 47.06 ± 0.80% (CS-AC), 53.84 ± 0.30% (CS-AC-EN), and 21.87 ± 0.60% (CS-AC-DIEN). By contrast, at intestinal pH, the release was slower and controlled, reaching 50.38 ± 0.10% for CS-AC at 72 h, 11.88 ± 0.50% for CS-AC-EN at 24 h, and 5.08 ± 0.30% for CS-AC-DIEN at 6 h. The release profiles were best fitted by the Korsmeyer–Peppas kinetic model. Antibacterial assays against S. aureus and E. coli showed that all three chitosan derivatives combined with CFZ outperformed CFZ alone and the mixture of unmodified chitosan with CFZ. The advantage was most pronounced after 72 h: against E. coli, all derivatives achieved >90% inhibition. These findings indicate that the chitosan derivatives are promising materials for controlling CFZ release in gastric and intestinal environments. Furthermore, when combined with CFZ, these derivatives demonstrate significant potential for antibacterial applications against Gram-positive and Gram-negative bacteria.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ACS Omega
ACS Omega Chemical Engineering-General Chemical Engineering
CiteScore
6.60
自引率
4.90%
发文量
3945
审稿时长
2.4 months
期刊介绍: ACS Omega is an open-access global publication for scientific articles that describe new findings in chemistry and interfacing areas of science, without any perceived evaluation of immediate impact.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信